Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch
A/S (NEUR) shall make public transactions with shares and related securities of
NeuroSearch A/S by persons discharging managerial responsibilities and
persons/companies closely associated with these.

Name: Flemming Pedersen
Reason:CEO
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 10,765
Market value (DKK): 1,679,771

Name: Frank Wätjen
Reason: Member of the Executive Management
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 6,745
Market value (DKK): 1,052,490

Name: Jørgen Drejer
Reason: Member of the Executive Management
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 7,177
Market value (DKK): 1,119,899

Name: Torben Skov
Reason: Member of the Board of Directors
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 2,007
Market value (DKK): 313,172
?
Name: Mads Gersdorff Korsgaard
Reason: Member of the Board of Directors
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 861
Market value (DKK): 134,350

Name: Anita Milland
Reason: Member of the Management Group
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 2,871
Market value (DKK): 447,991

Name: Dan Peters
Reason: Member of the Management Group
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 3,587
Market value (DKK): 559,715

Name: Dorthe Filtenborg Olesen
Reason: Member of the Management Group
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 1,291
Market value (DKK): 201,448

Name: Palle Christophersen
Reason: Member of the Management Group
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 2,871
Market value (DKK): 447,991

Name: Thomas Varming
Reason: Member of the Management Group
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 2,152
Market value (DKK): 335,798
?
Name: Daniel Brunicardi Timmermann
Reason: Member of the Management Group
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 2,152
Market value (DKK): 335,798

Name: Naheed Mirza
Reason: Member of the Management Group
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 4,162
Market value (DKK): 649,438

Name: Robin Sparks
Reason: Member of the Management Group
Issuer: NeuroSearch A/S
ISIN code: DK0010224666
Transaction: Exercise of warrants
Trade date: 15 March 2010
Market: NASDAQ OMX Copenhagen A/S
Number (pcs): 1,435
Market value (DKK): 223,917


Contact person:
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, tel: +45 4017 5103


About NeuroSearch - Company profile
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen A/S. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform, focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline, and licence collaboration with Abbott. The drug pipeline
comprises eight clinical (Phase I-III) development programmes: Huntexil®
(pridopidine) for Huntington's disease (Phase III), tesofensine for obesity
(ready for Phase III), ABT-894 for ADHD (Phase II) in partnership with Abbott,
ACR343 for schizophrenia (ready for Phase II), ACR325 to treat dyskinesias in
Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for
anxiety/depression (Phase I) and NSD-721 for social anxiety disorder (Phase I)
in partnership with GSK. In addition, NeuroSearch has a broad portfolio of
preclinical drug candidates and holds equity interests in several biotech
companies.

insideres handler - udnyttelse - 16.03.2010 - uk - final.pdf